According to the anti-VEGF agent, bevacizumab is a neutralizing antibody targeting VEGF protein; this antibody has been approved by Food and Drug Administration (FDA) for its application in metastatic colorectal cancer treatment, as well as in angiogenesis of various cancers [12,39,40]. This evidence concerns the gene VEGFA and metastatic colorectal cancer.